Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study.

ABSTRACT:

Background

Serious bleeding events have been frequently described in patients taking direct oral anticoagulants (DOAC). In secondary analyses of phase 3 trials, DOAC plasma concentrations were shown to correlate with bleeding outcomes. This study aimed to describe rivaroxaban plasma levels in patients admitted to the emergency department (ED) for bleeding events. For each patient, risk factors for experiencing bleeding events were also investigated.

Methods

This analysis was part of an observational study conducted in the ED of two teaching hospitals. Plasma samples from 10 rivaroxaban-treated patients admitted for bleeding events were collected. Rivaroxaban plasma concentrations were determined by calibrated chromogenic anti-Xa assay. The measured rivaroxaban levels were th

SUBMITTER: Sennesael AL 

PROVIDER: S-EPMC6231259 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature